Citeline?Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence, has partnered with Helium SEO to provide expert search engine optimization services to customers of its clinical trial website solution.
A recent survey on clinical trial participation conducted by Informa Pharma Intelligence and Rare Patient Voice revealed that 47% of those who have not participated in a clinical trial could not find nearby trials relevant to their disease/condition. Among participants, sources of online information included internet searches and pharmaceutical company websites; however, 77% of these respondents did not use ClinicalTrials.gov.
To help Citeline Connect-powered clinical trial websites rank higher in search results — driving traffic and, ultimately, recruiting clinical trial participants — Helium SEO provides the following services:
According to a BrightEdge study, organic search drives 53% of website traffic. What’s more, Moz statistics show that the?first?page?of Google search results captures as high as 92% of search traffic clicks. Google’s algorithm has more than 200 ranking factors, and it is constantly changing.
“As a technology professional, I know how crucial SEO is to the success of a website,” said Mike Wenger, Vice President of Patient Engagement for Informa Pharma Intelligence. “And, as a patient myself, I also know how frustrating it can be when you are searching for information online and come up empty-handed. That’s why at Citeline Connect we are thrilled to provide our trial website customers the level of expertise that Helium SEO offers.”
Timothy Warren, CEO of Helium SEO, emphasizes the importance of website optimization: “If your website cannot be found in Google search, your efforts are wasted. We’re excited to be working with Citeline Connect on optimizing these clinical trial websites and, in turn, to make them more accessible to patients.”
Check Out The New Martech Cube Podcast. For more such updates, follow us on Google News Martech News
Subscribe to our Newsletter